Use of IGIV in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis, and pretibial myxedema.

[1]  H. Hartung,et al.  Chronic inflammatory demyelinating polyneuropathy. , 2005, The New England journal of medicine.

[2]  S. Singhal,et al.  A complete and durable clinical response to high-dose dexamethasone in a patient with scleromyxedema. , 2004, Journal of the American Academy of Dermatology.

[3]  P. Gisondi,et al.  Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. , 2004, Journal of American Academy of Dermatology.

[4]  F. Lawlor,et al.  Successful treatment of scleromyxoedema with high dose intravenous immunoglobulin , 2004, Clinical and experimental dermatology.

[5]  Moses Rodriguez,et al.  Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a , 2004, Multiple sclerosis.

[6]  L. Mortier,et al.  Urticaire solaire traitée par l’association immunoglobulines polyvalentes et PUVAthérapie , 2004 .

[7]  A. Eisen,et al.  Scleromyxoedema: treatment of cutaneous and systemic manifestations with high‐dose intravenous immunoglobulin , 2003, The British journal of dermatology.

[8]  G. Dawn,et al.  Effect of high‐dose intravenous immunoglobulin in delayed pressure urticaria , 2003, The British journal of dermatology.

[9]  E. Bröcker,et al.  Lack of response of elephantiasic pretibial myxoedema to treatment with high‐dose intravenous immunoglobulins , 2003, Clinical and experimental dermatology.

[10]  R. Parslew,et al.  Superficial granulomatous pyoderma treated with intravenous immunoglobulin. , 2003, Journal of the American Academy of Dermatology.

[11]  B. Seitz,et al.  Annular Crystalline Keratopathy in Association With Immunoglobulin Therapy for Pyoderma Gangrenosum , 2003, Cornea.

[12]  S. Jolles.  Intravenous immunoglobulin in dermatology , 2003 .

[13]  S. Jolles,et al.  Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 counts. , 2003, Acta dermato-venereologica.

[14]  W. Sewell,et al.  Immunomodulatory action of intravenous immunoglobulin , 2002, Immunology.

[15]  S. Chevret,et al.  A randomized controlled evaluator‐blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis , 2002, The British journal of dermatology.

[16]  S. Whittaker,et al.  Psoriasis: response to high‐dose intravenous immunoglobulin in three patients , 2002, The British journal of dermatology.

[17]  A. Doria,et al.  Intravenous immunoglobulins control scleromyxoedema , 2002, Annals of the rheumatic diseases.

[18]  S. Chimenti,et al.  The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum , 2001, The Journal of dermatological treatment.

[19]  R. Asero.  Are IVIG for chronic unremitting urticaria effective? , 2000, Allergy.

[20]  I. Forgacs,et al.  Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). , 2000, Journal of the American Academy of Dermatology.

[21]  P. Seed,et al.  Randomized double‐blind study of cyclosporin in chronic ‘idiopathic’ urticaria , 2000, The British journal of dermatology.

[22]  G. Said.  Treatment of Neurological Disorders with Intravenous Immunoglobulins , 2000 .

[23]  W. Stolz,et al.  The effectiveness of low-dose intravenous immunoglobulin in chronic urticaria. , 2000, Acta dermato-venereologica.

[24]  S. Jolles,et al.  The treatment of atopic dermatitis with adjunctive high‐dose intravenous immunoglobulin: a report of three patients and review of the literature , 2000, The British journal of dermatology.

[25]  M. Kuo,et al.  Changes of serum levels of interleukin-2, intercellular adhesion molecule-1, endothelial leukocyte adhesion molecule-1 and Th1 and Th2 cell in severe atopic dermatitis after intravenous immunoglobulin therapy. , 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[26]  R. Stadler,et al.  Posttraumatisches Pyoderma gangraenosum: Kombinationstherapie mit intravenösen Immunglobulinen und systemischen Kortikosteroiden , 1999, Der Hautarzt.

[27]  K. Y. Lee,et al.  Intravenous immune globulin (i.v.IG) therapy in steroid-resistant atopic dermatitis. , 1999, Journal of Korean medical science.

[28]  P. Altmeyer,et al.  Successful treatment of pyoderma gangrenosum with intravenous human immunoglobulin. , 1998, Journal of the American Academy of Dermatology.

[29]  David B. Speights,et al.  High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[30]  T. Smith,et al.  Leukoregulin induction of protein expression in human orbital fibroblasts: evidence for anatomical site-restricted cytokine-target cell interactions. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Humphreys,et al.  The characteristics of urticaria in 390 patients , 1998, The British journal of dermatology.

[32]  S. Jolles,et al.  Management of aseptic meningitis secondary to intravenous immunoglobulin , 1998, BMJ.

[33]  Winkelmann,et al.  Intravenous immunoglobulin in autoimmune chronic urticaria , 1998, The British journal of dermatology.

[34]  S. Whittaker,et al.  Dermatological uses of high-dose intravenous immunoglobulin. , 1998, Archives of dermatology.

[35]  W. Sewell,et al.  The use of self infused intravenous immunoglobulin home therapy in the treatment of acquired chronic demyelinating neuropathies , 1997, Journal of neurology, neurosurgery, and psychiatry.

[36]  M. Morgan,et al.  The impact of chronic urticaria on the quality of life , 1997, The British journal of dermatology.

[37]  S. Schuval,et al.  Eczema and thrombocytopenia in an 8-month-old infant boy. , 1997, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[38]  R. Winkelmann,et al.  Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. , 1996, The Journal of investigative dermatology.

[39]  E. Gelfand,et al.  Intravenous immune globulin: an alternative therapy in steroid‐dependent allergic diseases , 1996, Clinical and experimental immunology.

[40]  N. Shear,et al.  Efficacy of human intravenous immune globulin in pyoderma gangrenosum. , 1995, Journal of the American Academy of Dermatology.

[41]  F. Simons,et al.  The pharmacology and use of H1-receptor-antagonist drugs. , 1994, The New England journal of medicine.

[42]  H. Kimata.  High dose gammaglobulin treatment for atopic dermatitis. , 1994, Archives of disease in childhood.

[43]  S. -. Wu,et al.  TSH and TSH receptor antibody-binding sites in fibroblasts of pretibial myxedema are related to the extracellular domain of entire TSH receptor. , 1994, Clinical immunology and immunopathology.

[44]  A. Antonelli,et al.  Pretibial myxedema and high-dose intravenous immunoglobulin treatment. , 1994, Thyroid : official journal of the American Thyroid Association.

[45]  S. Misbah,et al.  Adverse Effects of Intravenous Immunoglobulin , 1993, Drug safety.

[46]  J. Kochan,et al.  Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. , 1993, The New England journal of medicine.

[47]  A. Hirt,et al.  HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOOD , 1981, The Lancet.

[48]  R. Furth,et al.  Scleromyxoedema (lichen myxoedematosus) associated with a paraprotein, IgG1 of type kappa , 1973, The British journal of dermatology.

[49]  D. Fisher,et al.  Pyoderma gangrenosum associated with hypogammaglobulinemia; report of two cases. , 1958, A.M.A. archives of dermatology.

[50]  P. V. Marcussen.  Hypogammaglobulinemia in pyoderma gangrenosum. , 1955, The Journal of investigative dermatology.